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INTRODUCTION
Choline kinase alpha (ChoKα) has become the 
subject of intense interest for its utility as an oncogenic 
biomarker as well as an anticancer therapeutic target 
[1–5]. ChoKα catalyzes choline phosphorylation as 
an intermediate step in the synthesis of two abundant 
membrane phospholipids, phosphatidylcholine (PtdCho) 
and sphingomyelin. Elevated ChoKα activity has 
been identified in approximately 40% of human breast 
tumors [6], and aberrant choline metabolism has been 
reported in lung, breast, colorectal, prostate, brain, 
bladder, and pancreatic cancers [7–10]. ChoKα produces 
phosphocholine (PC), which is critical for cell growth 
and for the regulation of cell proliferation by growth 
factors [11]. During malignant transformation, cells 
sequester high levels of PC that are detectable using 1H 
magnetic resonance spectroscopy (MRS) due to the nine 
chemically-equivalent protons on the methyl groups of the 
quaternary nitrogen [12,13]. ChoKα can be activated by 
the Ras and RhoA oncogenes, although overexpression of 
ChoKα alone is sufficient to transform cells to a malignant 
phenotype [14–16].
ChoKα inhibitors have been developed to study the 
involvement of this enzyme in malignant transformation. 
Shutting down de novo phospholipid biosynthesis leads 
to lower levels of pro-mitotic second messenger Kennedy 
pathway intermediates, increased ceramide levels, and 
de-stabilized endoplasmic reticulum [2, 17–19]. The most 
potent of these agents, TCD-717, is a promising anti-
cancer drug [19] that is being evaluated in clinical trials 
[20]. MN58b, a bis-cationic ChoKα inhibitor, has been 
demonstrated to be lethal to lymphoma cells, but causes a 
reversible cell cycle arrest in normal cells [17]. Although 
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ABSTRACT
Choline kinase alpha (ChoKα) overexpression is associated with an aggressive 
tumor phenotype. ChoKα inhibitors induce apoptosis in tumors, however validation 
of their specificity is difficult in vivo. We report the use of optical imaging to assess 
ChoKα status in cells and in vivo using JAS239, a carbocyanine-based ChoKα inhibitor 
with inherent near infrared fluorescence. JAS239 attenuated choline phosphorylation 
and viability in a panel of human breast cancer cell lines. Antibody blockade prevented 
cellular retention of JAS239 indicating direct interaction with ChoKα independent of 
the choline transporters and catabolic choline pathways. In mice bearing orthotopic 
MCF7 breast xenografts, optical imaging with JAS239 distinguished tumors 
overexpressing ChoKα from their empty vector counterparts and delineated tumor 
margins. Pharmacological inhibition of ChoK by the established inhibitor MN58b led 
to a growth inhibition in 4175-Luc+ tumors that was accompanied by concomitant 
reduction in JAS239 uptake and decreased total choline metabolite levels as measured 
using magnetic resonance spectroscopy. At higher therapeutic doses, JAS239 was as 
effective as MN58b at arresting tumor growth and inducing apoptosis in MDA-MB-231 
tumors, significantly reducing tumor choline below baseline levels without observable 
systemic toxicity. These data introduce a new method to monitor therapeutically 
effective inhibitors of choline metabolism in breast cancer using a small molecule 
companion diagnostic.
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the mechanism by which ChoKα inhibition causes cell 
death may involve scaffolding in addition to enzymatic 
functions [21], measurement of total choline-containing 
metabolite (tCho) levels by MRS is still the primary 
method of validating ChoK inhibitors in vivo [22, 23]. A 
limitation of this approach is that metabolite levels are also 
affected by the contributions of phospholipases, organic 
cation transporters, and sphingomyelinases [3, 24, 25]. 
Moreover, cell death can lead to deceptive decreases 
in tCho in MR spectra, requiring the measurement of 
secondary biomarkers [26, 27]. 18F and 11C choline PET 
tracers are useful for identifying ChoK inhibition [28], 
but choline tracer accumulation can be affected by choline 
transport inhibitors [29, 30] which have known toxicities 
[31]. In addition, recent reports have shown that ChoKα 
protein scaffolding, rather than the enzymatic function, 
may be critical for supporting cell viability [21, 32, 33]. 
Miyake and Parsons reported a c-Src-dependent link 
between ChoKα and EGFR [32]. More recent studies 
showed that small molecule non symmetric ChoKα 
inhibitors with low nM IC50s could substantially reduce 
the metabolic product PC but only cause reversible 
growth arrest with no effects on cell viability [21, 33]. 
Thus further development of fluorescence-based imaging 
strategies that report on enzyme expression rather than 
enzyme activity is needed.
We have recently reported fluorescent small 
molecule choline mimetics (JAS239) that effectively 
attenuate choline phosphorylation. The structural 
similarity between symmetric, bis-heterocyclic ChoKα 
inhibitors and a class of carbocyanine dyes used for 
optical imaging led to the development of these enzyme 
inhibitors with near infrared fluorescence (NIRF) [4]. 
Within this wavelength range human tissue is relatively 
transparent [34–36] and NIRF optical imaging probes 
can be detected through several millimeters, and up to 
centimeters of tissue [37, 38]. Moreover, these probes 
exhibit a concentration dependent cellular uptake that 
cannot be attenuated in the presence of excess free choline 
indicating that they enter the cell independently of the 
choline transporters [4]. There is a particular need for 
more specific agents to assist surgeons in distinguishing 
tumor from normal tissue [36, 39], and intraoperative 
imaging is an expanding field for which NIRF offers an 
inexpensive and effective method of delineating tumor 
margin and assessing lymph node involvement [40–42]. 
In this work we investigate JAS239 as a NIRF ChoKα-
targeted optical imaging probe in murine orthotopic 
breast tumors and compare this diagnostic method to 
MRS. In vitro, JAS239 was validated against MN58b and 
shown to have comparable potency to block cell growth 
and inhibit choline phosphorylation in breast cancer cell 
lines. In vivo, we demonstrate that JAS239 can be used 
to distinguish overexpression of ChoKα in breast tumor 
models and monitor ChoKα inhibition induced by MN58b. 
At higher doses, JAS239 was compared to MN58b to 
assess the therapeutic potential of ChoKα inhibitors in 
these tumor models. A therapeutic course of JAS239 was 
able to significantly reduce tumor tCho levels, reduce 
tumor cell density, decrease proliferation, and cause 
apoptosis and tumor growth arrest. 
RESULTS
Characterization of inhibitor sensitivity in a 
breast cancer cell line panel
Inhibition of ChoKα by JAS239 and MN58b 
was measured in 4 breast cancer cell lines, MCF7 
overexpressing ChoK (MCF7-CK+) [47], the 
corresponding empty vector cell line (MCF7-EV), MDA-
MB-231, and 4175-Luc+, an MDA-MB-231 derivative 
harvested from a lung metastasis and transfected with 
luciferase [43]. The MCF7-CK+ line was confirmed to 
have elevated ChoKα expression and activity relative to 
MCF7-EV cells (Supporting Information, Supplementary 
Figure 1A–1B) [4]. No significant difference in ChoKα 
expression or activity was observed between the 
triple-negative MDA-MB-231 and 4175-Luc+ lines 
(Supplementary Figure 1A–1B). MN58b attenuated the 
elevated ChoKα activity in MCF7-CK+ cells with similar 
efficacy to the control MCF7-EV cell line as indicated by 
the IC
50
 (Table 1, Supplementary Figure 1C). Similarly, 
no significant difference in IC
50
 was found between the 
MDA-MB-231 and the 4175-Luc+ cell lines after 2 h of 
MN58b treatment (Table 1, Supplementary Figure 1D). 
MN58b was at least twice as effective as JAS239 at 
reducing choline phosphorylation at 2 h in all cell lines 
tested (Table 1, Supplementary Figure 1E–1F). 
Extended treatment of cancer cells with ChoK 
inhibitors leads to cell death by apoptosis [19]. After 
17 h, we found no significant difference in the EC
50
s 
between MN58b (Table 1, Supplementary Figure 2A) and 
JAS239 in the MCF-7 EV and CK+ cell lines (Table 1, 
Supplementary Figure 2B) by Trypan blue exclusion. As 
was found in radiotracing assays, MN58b was more potent 
at inhibiting cell growth than JAS239 in MDA-MB-231 
and 4175-Luc+ cells although the results were more 
variable (Table 1, Supplementary Figure 2C–2D). 
JAS239 colocalization with ChoKα 
Fluorescence confocal micrographs of fixed 
MDA-MB-231 cells treated with JAS239 and an anti-
human ChoKα antibody are shown in Figure 1, top. 
When treated individually, no overlap was observed 
between the Texas-Red (ChoKα antibody) and JAS239 
channels (see also Supplementary Figure 3A). MDA-
MB-231 cells stained with JAS239 and probed with 
the ChoKα antibody revealed strong colocalization 
(Figure 1, middle and Supplementary Figure 3A). Of the 
ChoKα-positive pixels, 89 + 9% were also positive for 
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JAS239 (Supplementary Figure 3B). Similarly, 89 + 10% 
of JAS239-positive pixels were positive for ChoKα 
(Supplementary Figure 3C). When cells were pre-treated 
with ChoKα antibody, marked reduction in JAS239 
retention was detected (Figure 1, bottom). Reduced 
JAS239 signal caused a lower Pearson’s Correlation 
Coefficient, although 84 + 4% of the regions which 
were ChoKα-positive were also JAS239-positive (see 
Supplementary Figure 3B), and 87 + 2% of the JAS239-
positive pixels were ChoKα-positive (see Supplementary 
Figure 3C). This demonstrates that JAS239 retained in 
these cells was still associated with ChoKα, even though 
the intensities followed a different distribution trend. 
These results are consistent with JAS239 being out-
competed by the antibody for binding sites. 
NIRF imaging facilitates study of JAS239 
biodistribution
Tumors derived from 4175-Luc+ cell lines had 
the most rapid in vivo growth (see Supplementary 
Figure 4A–4B) that could additionally be monitored 
Table 1: Potency of MN58b and JAS239 in a panel of breast cancer cell lines
IC50 (μM) EC50 (μM)
Cell Line MN58b JAS239 MN58b JAS239
MCF7-EV 3.85 ± 0.42 11.1 ± 5.64 3.29 ± 0.48 4.04 ± 0.55
MCF7-CK+ 2.36 ± 0.28 10.3 ± 2.48 6.86 ± 0.43 5.33 ± 0.84
MDA-MB-231 4.36 ± 1.37 9.92 ± 0.22 14.26 ± 4.6 27.2 ± 7.9
4175-Luc+ 4.59 ± 0.55 9.89 ± 0.24 20.7 ± 6.4 35.0 ± 21.6
Cells were treated with varying concentrations of MN58b or JAS239 and analyzed after 2 h for 14C-PC production or after 
17 h for cell viability. Data for 3 separate experiments were fitted to sigmoidal plots and IC
50
s and EC
50
s are reported + SEM 
for the radiotracing and viability assays, respectively.
Figure 1: JAS239 colocalizes with ChoKα. Fixed permeabilized MDA-MB-231 cells treated with a ChoKα-specific antibody (Ab) 
followed by a Texas Red-conjugated secondary antibody (Ex. 543 nm; Em. 565–615 nm) were assessed by confocal microscopy (top row). 
In cells stained with JAS239 followed by the ChoKα antibody (middle row), strong colocalization between the JAS239 (Ex. 633 nm; Em. 
> 650 nm) and ChoKα is observed. Cells incubated with ChoKα antibody prior to JAS239 staining (bottom row) no longer retain the NIRF 
probe. Scale bar represents 35 μm.
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with bioluminescence imaging. Bioluminescence in mice 
bearing orthotopic 4175-Luc+ tumors was measured 
15 min following luciferin injection (Supplementary 
Figure 5A). This signal was used to delineate the tumor 
margins (in blue) and was used to confirm that the 
bioluminescence did not overlap with the NIR range 
(Supplementary Figure 5B). The next day no residual 
luminescence was detected, and mice were treated with 
control vehicle (Figure 2A, left mouse) or 20 nmol JAS239 
in Tween-80/Tris buffer (Figure 2A, right mouse). After 
initial hepatic clearance (approximately 75 min), mice were 
injected i.p. with luciferin and imaged for bioluminescence 
and NIRF 15 min later. Bioluminescence was again used 
to delineate the tumor margin (Supplementary Figure 5C), 
and no NIRF signal was detected in the control animals 
(Figure 2A, left mouse; n = 5). In the JAS239-injected 
animals, NIRF was emitted both from the tumor and 
from the kidneys (Figure 2A, right mouse; n = 4). NIRF 
emission at 800 nm was an order of magnitude stronger 
in JAS239-injected animals vs. control (Figure 2B). 
The maximum NIRF contrast between the tumor and 
background was achieved 90 minutes post-JAS239 
injection, tumor fluorescence diminished after this time 
due to excretion Supplementary Figure 5D). 
Mice from this cohort were injected one week later 
(allowing the first dose to clear entirely) with JAS239, 
euthanized 90 min later, and the organs resected and 
imaged (Figure 2C). The biodistribution of JAS239 is 
consistent with the renal signal detected in whole animals, 
however the signal from other organs (liver in particular) 
was higher than would be expected from whole-body 
images (Figure 2D). The tumor contrast seen in whole-
body NIRF images is enhanced due to the relative depth 
of these organs, compared to the surface tumor. 
A cohort of 5 mice was inoculated with 
subcutaneous 4175-Luc+ tumors high on the right flank. 
This cohort was injected with JAS239 in an ethanol/saline 
vehicle. Fluorescence from the kidneys was the dominant 
source of NIRF signal (Figure 2E). Intentional placement 
of these tumors on the shoulders allowed us to cloak the 
lower extremities and isolate the tumor for NIRF imaging 
(Figure 2F). Tumor signal to noise was highest at 24 h 
and the organs in these animals were resected and imaged 
to estimate biodistribution (Figure 2G). Compared to the 
Tween-80/Tris vehicle, hepatic signal from JAS239 in 
this formulation dropped nearly one order of magnitude, 
drastically reducing background signal (Figure 2H). At 
this time, a nearly two-fold tumor-to-muscle ratio was 
found ex vivo (Figure 2I).
Optical imaging of JAS239 to assess ChoKα status
The effect of genetic overexpression of ChoKα on 
JAS239 retention was studied in mice bearing orthotopic 
MCF7-EV and MCF7-CK+ tumors (Figure 3A) that 
were injected with JAS239 in ethanol/saline vehicle. 
Optical imaging of the surgically exposed mammary fat 
pads revealed distinct NIRF signal within the confines 
of the orthotopic tumor, and tumor margins could clearly 
be delineated (Figure 3B). JAS239 accumulation was 
significantly higher in MCF7-CK+ tumors compared to 
contralateral MCF7-EV tumors (Figure 3C). A significant 
but more moderate increase in NIRF was observed 
between exposed MCF7-EV and MCF7-CK+ fat pad 
tumors in mice injected with JAS239 in Tween-80/Tris 
buffer 90 min prior (see Supplementary Figure 5E). 
MN58b treatment was used to model pharmacologic 
inhibition of ChoKα. Mice bearing orthotopic 4175-Luc+ 
tumors were imaged with in vivo MRS and then treated 
with a 5-day dose regimen of MN58b at 2 mg/kg/day i.p. 
In vivo MRS 7 days later (Figure 3D–3E) showed reduced 
tCho levels after MN58b treatment (Figure 3E–3F). In 
control-treated animals tCho levels increased substantially 
during the one-week period (Figure 3F). These animals 
underwent post-treatment JAS239 injections with follow-
up NIRF imaging (Figure 3G), and MN58b treatment 
reduced intratumoral JAS239 accumulation relative to 
untreated tumors (Figure 3H).
JAS239 is a therapeutically effective ChoKα 
inhibitor in breast xenograft models
To test the therapeutic potential of JAS239, a group 
of athymic nude mice with 4175-Luc+ tumors were given 
a 5-day i.p. dose treatment regimen of JAS239 or MN58b 
beginning 3 days after orthotopic tumor inoculation. Both 
2 mg/kg/day MN58b-treatment and 4 mg/kg/day JAS239-
treatment resulted in significantly smaller tumor volumes 
compared to control animals (Figure 4A). Until day 26, 
both the MN58b and JAS239 cohorts had significantly 
smaller (P = 0.021 and 0.022, respectively) tumors than 
the vehicle-treated group. 
To study the metabolic effects of JAS239 therapy 
on tumors, tCho was used as a pharmacodynamic 
marker of ChoKα inhibition (Figure 4B). MDA-MB-231 
xenografts were used because prior characterization 
of MN58b in this model [22] allowed for the confident 
use of this inhibitor as a positive control. MRI volume 
measurements indicated that vehicle-treated tumors grew 
during the week between pre- and post-treatment MRS 
scans (Paired t-test: P = 0.009), whereas MN58b-treated 
and JAS239-treated tumors were static during the same 
time span (Supplementary Figure 6A). Single voxel 
MRS in each tumor (Supplementary Figure 6B–6D), 
showed that tCho increased during the treatment 
course (Figure 4B– 4C). Significant reductions in tCho 
compared to control were observed in response to MN58b 
(P = 0.006, Figure 4B– 4D) and JAS239 (P = 0.004, Figure 
4B– 4E). JAS239 treatment was able to reduce tCho to 
noise levels in these tumors. Polyunsaturated fatty acid 
(PUFA) resonances, a measure of tumor apoptosis [48], 
increased after MN58b and JAS239 treatment, although 
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this trend was not significant (Supplementary Figure 6E). 
Supplementary Figure 6F depicts a summary of the 
toxicology of the mice from this experiment, revealing 
no significant effects except for elevation of blood urea 
nitrogen in MN58b-treated animals compared to controls 
(P = 0.012). 
Tumors from MDA-MB-231-bearing mice were 
harvested for histological assessment immediately after 
follow-up MRI/MRS scanning (Figure 5A). Evaluation 
of H&E slides (Figure 5B) showed that both MN58b 
(P = 0.007) and JAS239 (P = 0.01) caused significant 
reduction in cell density. MN58b (P = 0.026) and JAS239 
(P = 0.034) treatment significantly reduced the percentage 
of Ki67-positive cells compared to the control group 
(Figure 5C). Consistent with reduced cell number and 
proliferation, higher caspase-3 levels (Figure 5D) were 
detected in MN58b (P = 0.016) and JAS239 (P = 0.015) 
treated tumors than in controls. 
DISCUSSION
JAS239 is a ChoKα inhibitor whose inherent near 
infrared fluorescence makes it possible to measure its 
interaction with cancer cells. In this study, we investigated 
Figure 2: In vivo optical imaging provides JAS239 biodistribution data. (A) Tumor margin (blue) defined by bioluminescent 
imaging of 4175-Luc+ tumors shows no NIRF in vehicle-injected mouse (left) but intratumoral NIRF in right mouse injected with 
JAS239 in Tween-80/Tris Buffer. Renal excretion of JAS239 is also seen outside the tumor boundaries. (B) Quantified Average Radiant 
Efficiency [p/sec/cm2/sr]/[μW/cm2] in tumor ROIs (n = 4). (C, D) Organs resected 90 min following JAS239 injection imaged for NIRF 
(C) and quantified for comparison. (E) Delivered in an ethanol/saline formulation, maximal intratumoral JAS239 (white arrow) relative to 
background was achieved 24 h post-injection. (E, F) Tumors (white arrow) moved to shoulder allow organs involved in JAS239 excretion 
to be cloaked. (G, H) Resected organs 24 h post-injection of JAS239 imaged for NIRF (G) and quantified (H). (I) Tumor and muscle NIRF 
were quantified and were found to be significantly different. Unless otherwise noted, cohort size was 5 animals and values represent + SEM. 
Total JAS239 delivered was 20 nmol/animal.
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the ability of JAS239 to detect ChoKα expression in 
human xenograft models of breast cancer. We first 
verified the response to ChoKα inhibition by JAS239 in a 
panel of human breast cancer cells representing different 
germ lines (epithelial and mesenchymal), tumor stages 
(estrogen-positive and triple-negative), derivation (mouse-
naïve and mouse-adapted), and ChoKα expression (low 
and high). Using confocal microscopy, JAS239 staining 
was compared with ChoKα expression measured using 
immunohistochemistry. Colocalization of the probe with 
ChoKα was observed, indicating a direct interaction that 
could be blocked when the N-terminal antibody was 
applied first. This is consistent with a mechanism of 
competitive inhibition of the active site of ChoKα [4].
Against pure yeast ChoKα, the average reported 
IC
50
s of the bis-pyridinium and bis- quinolinium ChoKα 
inhibitors are 37.1 and 33.9 μM, respectively; the 
antiproliferative activities, EC
50
s, in HT-29 cells are 19.7 
and 3.7 μM, respectively [49–50]. Although determined in 
different systems, the measured IC
50
 of 4.6 μM for JAS239 
represents potency comparable to or better than 85% of 
the reported bis-pyridinium–based ChoKα inhibitors, and 
61% of the bis-quinolinium compounds. The EC
50
 values 
are also comparable, although determined using different 
assays in cell lines of different tissue origin. The action 
of JAS239 against MDA-MB-231 cells suggests ChoKα 
inhibition may be an effective strategy in triple- negative 
breast cancers, which are often therapy resistant. Its 
potency suggests that further modifications based upon the 
carbocyanine template, and subsequent structure–activity 
characterization, may yield compounds with higher 
specificity to ChoKα.
While in vitro data can often be promising, 
translation to in vivo models is crucial for a true 
assessment of the efficacy and feasibility of this 
technology. In vivo biodistribution showed that JAS239, 
a cationic small molecule, accumulated and was cleared 
through the kidneys. An initial flush was observed in the 
liver where ChoKα is naturally abundant [51], but this is 
also the site of first-pass metabolism. With the guidance of 
bioluminescence imaging in 4175-Luc+ tumor xenografts, 
intratumoral JAS239 NIRF was detectable but eventually 
drowned out by renal filtration and excretion of the probe. 
This result does not disparage the translational utility 
Figure 3: NIRF imaging for JAS239 accumulation can detect genetic overexpression and pharmacologic inhibition 
of ChoKα. (A) Athymic nude mice were inoculated with MCF7-EV (left mammary fat pad) and MCF7-CK+ (right mammary fat pad) 
cells. (B) Tumor-bearing fat pads were surgically exposed and imaged for NIRF 24 h after JAS239 injection in an ethanol formulation. 
(C) Quantified Average Radiant Efficiency [p/sec/cm2/sr]/[μW/cm2] of resected fat pads reveals enhanced JAS239 retention in ChoKα-
overexpressing tumors (n = 7). (D) Representative T
2
-weighted MR image of a 4175-Luc+ tumor used to plan 3x3x3 mm3 voxel placement. 
(E) In vivo MR spectra of the choline (3.2 ppm) and PUFA (2.8 ppm) regions for control (black) and MN58b-treated (red) tumors. (F) 
MN58b-treatment prevents the increase in intratumoral tCho (3.2 ppm) observed between scans in the control cohort. (G, H) NIRF of 
the exposed saline (left) or MN58b-treated (right) tumors (G) was quantified and MN58b-induced ChoKα inhibition diminishes JAS239 
retention significantly (H). For saline and MN58b groups, n = 5. Values are reported as ± SEM.
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of this probe, as clinical optical imaging is not a whole-
body but rather a tissue or region-specific measurement, 
especially when employed in an intraoperative setting [39]. 
While biodistribution studies showed that JAS239 
could be detected in other major organs, the tumor/muscle 
ratio suggests that measurements confined to the breast 
region were robust enough to distinguish malignant from 
normal tissue. This was further verified when tumor-
bearing mammary fat pads of JAS239-injected mice 
were surgically exposed and imaged with NIRF optical 
imaging. JAS239 accumulation was found to be a reliable 
identifier of ChoKα overexpressing tumors in matched 
MCF7-EV and CK+ tumors. Although the difference in 
JAS239 fluorescence between EV and CK+ tumors was 
moderate, the observed tumor/normal tissue fluorescence 
ratio of 2.8 ± 0.2 was sufficient to distinguish malignant 
from normal tissue and is similar to values reported for 
other agents currently being used for fluorescence-guided 
tumor resection [42]. To assess the validity of this imaging 
strategy we employed the well-studied ChoKα inhibitor 
MN58b as a positive control [17, 19, 52] and evaluated 
the effects of MN58b therapy in tumor-bearing mice with 
NIRF imaging and MRS. The parallel use of two imaging 
techniques indicated a more complete story: MN58b bound 
to tumor ChoKα (blocking JAS239 accumulation) thus 
attenuating flux through the Kennedy pathway (lowering 
tCho signals). It is important to note that the 25 + 30% 
reduction in tCho measured by in vivo MRS was mirrored 
by the 25 + 8% reduction in JAS239 accumulation, but 
NIRF measurements were less variable between animals 
resulting in greater statistical confidence. Moreover, 
optical imaging was easier to perform. While MRS 
required 1 h per mouse — including set-up, anesthesia, 
shimming, and scanning — the optical imaging technique 
could be performed on up to 5 mice simultaneously and 
required a simpler procedure involving one i.v. injection 
and follow-up surgery 24 h later.
To explore the therapeutic properties of JAS239, 
its ability to inhibit tumor growth and attenuate tCho in 
murine breast xenografts was determined. In orthotopic 
breast tumors, JAS239 significantly reduced tumor growth 
rate to the same degree as MN58b. MN58b at 4 mg/kg 
had previously been reported to lower PC levels in 
MDA-MB-231 tumor xenografts [22]. No observable or 
measurable toxicity was found using 4 mg/kg JAS239, 
and 2 mg/kg MN58b appeared tolerable but post-mortem 
toxicological studies revealed evidence of elevated blood 
urea nitrogen indicative of impaired renal function in these 
mice. Prior reports indicated MN58b to be tolerable when 
dosed daily for 5 days at 5 mg/kg, but lethal at 10 mg/kg 
Figure 4: JAS239 exhibits ChoKα inhibition and slows breast tumor growth. (A) Treatment for 5 consecutive days with 2 mg/kg 
of MN58b (n = 4) or 4 mg/kg of JAS239 (n = 5) significantly reduced the growth rate of orthotopically-implanted 4175-Luc+ tumors, 
compared to control animals (n = 4). (B–E) The change in tCho (3.2 ppm) within MDA-MB-231 tumors was measured using MRS (B) to 
show progressive tCho increase during saline treatment (n = 5) (B, C), whereas reductions in tCho in response to 5 days of 2 mg/kg MN58b 
(n = 4) (B, D) or 4 mg/kg JAS239 (n = 3) (B, E) were observed. Values are reported as ± SEM, *indicates P < 0.05 compared to the control 
group.
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[52]. An optimized bis-pyridinium ChoKα inhibitor was 
recently shown effective at 10 mg/kg daily for 3 days, 
and body weight measurements indicated no adverse 
toxicities [53]. Both JAS239 and MN58b were capable of 
significantly reducing intratumoral tCho and increasing 
PUFA resonances associated with apoptosis [23, 48]. 
However, JAS239 was more effective at reducing tumor 
tCho, decreasing the levels down to baseline noise. In 
control tumors, rising tCho measured by in vivo MRS was 
an indicator of tumor growth during the week between 
pre- and post-therapy. Tumor status was also evaluated 
by histological methods. Both ChoK inhibitors effectively 
reduced cell number, reducing the proliferation marker 
Ki67 and inducing widespread cell death via apoptosis.
Expanding interest in ChoKα inhibitors for cancer 
therapy has raised the need for rapid and reliable methods 
to validate these therapies in vivo [5]. There have been 
concerns with the reliability of RECIST measurement as a 
marker of treatment responsiveness [54]. An addendum to 
the first clinical trial of TCD-717 included MRS evaluation 
of tCho levels as a supplemental treatment response 
indicator (Clinical Trials identifier: NCT01215864). MRS 
is the current gold standard for choline measurement in vivo 
due to its specificity, non-invasive acquisition, and feasible 
inclusion following MRI for RECIST measurements. 
To understand the degree to which choline metabolites 
represent a real biomarker of tumor progression and 
response to therapy, it is crucial to develop methods of 
identifying the oncogenes that contribute to heightened 
choline in cancerous tissue. ChoKα has been reported 
throughout the literature as a key contributor to aberrant 
choline metabolism [55], and its regulative role in cell 
growth and division directly links the Kennedy pathway 
to cancer malignancy. The use of NIRF choline mimetics 
to determine ChoKα status in whole tumors will provide a 
measure of histological tumor grade, a potential indicator 
of tumor margins during surgical resection, and a validation 
method for evaluating ChoKα inhibitors in the clinic.
Figure 5: Histological assessment of tumors reveals reduced cell density, lower proliferation, and elevated apoptosis 
in response to ChoKα inhibitors. (A) H&E staining (left column) of MDA-MB-231 tumor xenografts reveals lower cell density in 
MN58b (middle row) and JAS239 (bottom row) treated tumors compared to vehicle-treated tumors (top row). Reduced Ki67-positive 
nuclei (middle column) and heightened caspase-3 positive cells (right column) were also found in MN58b and JAS239 treated tumors. 
Significant (B) reduction in cell density, (C) lower Ki67 positivity, and (D) elevated caspase-3 were observed in both MN58b and JAS239 
treated tumors relative to control, indicating apoptosis in response to ChoK inhibition. Scale bars represent 200 μm. Values are reported as 
± SEM and n = 3 for each treatment cohort. *indicates P < 0.05.
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MATERIALS AND METHODS
Cell lines: MDA-MB-231 human breast cancer cells 
were obtained from the ATCC and authorized via COI 
assay, STR analysis, and BacT/ALERT 3D. The 4175-
Luc+ cell line, transfected to express luciferase and green 
fluorescent protein and derived from a MDA-MB-231 
lung metastasis [43], was acquired from Dr. Andy Minn 
and maintained in 5 μg/mL blasticidin (Invitrogen), which 
was not included during experiments. Both cell lines were 
maintained in DMEM (Mediatech). MCF7 breast cancer 
cells (Chk-4 clone, MCF7 CK+) or the empty vector 
(MCF7 EV) were provided by Drs. Zaver Bhujwalla 
and Tariq Shah [44] and cultured in MEM (Mediatech) 
supplemented with 400 mg/mL G418 sulfate (Mediatech) 
that was not included during experiments. All cells were 
supplemented with 10% FBS (HyClone Laboratories), 
1% penicillin/streptomycin (Mediatech), and 1% 
L-glutamine (Mediatech), and kept in a 37°C humidified 
atmosphere (5% CO
2
). Cell lines were tested bi-monthly 
for mycoplasma. Cells were frozen in liquid nitrogen and 
used only at low passage numbers. Each cell line was 
characterized for ChoKα expression by Western blot [4].
Cell viability assays
MCF7 cells were plated for Trypan exclusion assays 
at 1.0 x 106 cells/well in 6-well plates and treated with 
MN58b or JAS239, synthesized in house [4]. At 17 h, 
cells were collected by trypsinization, stained with Trypan 
Blue, and counted using a Neubauer hemocytometer. 
For 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assays, cells in 96-well plates (7.5 × 104 
cells/well) were treated with JAS239 or MN58b overnight, 
and stained with 20 μL of 5 mg/mL MTT (Sigma-Aldrich) 
for 2 h, lysed with DMSO and scanned for absorbance 
using a SpectraMax M5 plate reader (Molecular Devices) 
at 550 nm, subtracting background absorbance at 690 nm 
from each sample.
Chokα activity assay
Cells in 6-well plates (1.0 × 106 cells/well) were 
incubated for 24 h then treated with JAS239 or MN58b. 
After 1 h, cells were spiked for 1 h with 0.5 μCi/mL 
[methyl-14C]-choline (PerkinElmer) and fixed with 
trichloroacetic acid. Aqueous cellular extracts were 
separated by thin layer chromatography (TLC) and the 14C-
PC production measured by autoradiography on a Fujifilm 
FLA-7000 using previously described methods [4, 23]. 
Confocal microscopy
MDA-MB-231 cells plated on sterile glass 
coverslips were fixed in 4% paraformaldehyde, 
permeabilized in 0.2% Triton X-100, and blocked in 1% 
BSA. Staining with 0 or 200 μM JAS239 was performed 
30 min prior or 1 h after application of rabbit anti-human 
ChoKα antibody (ab38290; Abcam, 1:1000 dilution). 
Coverslips were then stained with goat anti-rabbit 
antibody conjugated to Texas Red (Vector Laboratories; 
TI-1000, 1:500), dehydrated, and mounted with 
VectaShield (Vector Laboratories). Confocal micrographs 
were acquired on a Zeiss LSM 510META NLC using 
excitation (Ex.) 543 nm and emission (Em.) 565–615 
nm for Texas Red and Ex. 633 nm and Em. > 650 nm 
for JAS239. The Coloc 2 FIJI software plug-in was used 
to assess colocalization of the anti-ChoKα antibody with 
JAS239 by calculating Pearson’s Correlation Coefficients 
and Manders’ Colocalization Coefficients for at least 3 
separate ROIs [45].
Animal model and tumor cell implantation
All animal studies were approved by the Institutional 
Animal Care and Use Committee of the University of 
Pennsylvania. Six week old female athymic nude Foxn1nu/nu 
mice (National Cancer Institute) were housed in a 
temperature-controlled environment with 12 h light/dark 
cycle. Anesthesia was induced using 2% isoflurane in 
oxygen for all experiments. For MCF7 tumors, mice were 
supplemented with 60-day release 0.36 mg 17β-estradiol 
tablets (Innovative Research of America) using a trochar 
in the nape of the neck. After 1 week, 4 × 106 cells in 
Matrigel (BD Biosciences) were inoculated into the 
left (CK+) and contralateral (EV) mammary fat pads. 
Subcutaneous xenografts, including those analyzed in 
MRI/MRS studies, were grown on the shoulder to allow 
for cloaking of the kidneys during optical imaging studies. 
Tumor growth was determined via caliper measurement 
of three orthogonal dimensions and volume calculated as 
length * width * height * π/6.
Optical imaging
Bioluminescence and NIRF (Ex. 745 nm; Em. 
800 nm) images were acquired in an IVIS Spectrum 
(PerkinElmer). NIRF is measured in Average Radiant 
Efficiency, photons per second (p/sec) corrected for the 
area of the region of interest (ROI) and the efficiency of 
the lamp (μ Watt *cm−2 / steradian-1). For bioluminescence 
imaging, mice were injected i.p. with 150 mg/kg of firefly 
D-luciferin (Biosynth). Bioluminescent Radiance (p/sec/
cm2/sr) was monitored by time-course imaging until the 
luminescence intensity plateaued. For NIRF imaging, 
mice were injected i.v. with 100 μL vehicle or JAS239 
(20 nmol). Two vehicle formulations were tested in mice 
bearing 4175-Luc+ tumors: the first was 0.1% Tween-80 / 
50 mM Tris-HCl, and the second was 1% ethanol diluted 
in 0.9% saline. ROIs with a 20% threshold were created 
from the bioluminescence image using the LivingImage 
software (PerkinElmer) program, and this region was used 
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to analyze intratumoral JAS239 accumulation in the NIRF 
images. Resected organs were placed in 24-well plates and 
NIRF was measured to quantify JAS239 biodistribution. 
For diagnostic studies, mice bearing both MCF7-EV 
and MCF7-CK+ tumors of approximately 200 μL were 
injected with 20 nmol JAS239 in Tween-80/Tris (8 mice) 
or in ethanol/saline (7 mice). The cohorts were euthanized 
after 90 min / 24h respectively, and tumor-bearing flanks 
were surgically exposed. NIRF from the tumor-bearing fat 
pads was subtracted from background muscle signal and 
the Average Radiant Efficiency measured. 
In vivo MRI
Animal preparation
A mouse was anesthetized and secured to a custom-
built restraining device to minimize motion artifacts 
and the head positioned within a nose cone delivering 
isoflurane. A respiration pillow was placed dorsally to 
monitor respiration rate, and a thermister was inserted 
rectally to measure body temperature. Both sensors 
were connected to a small animal monitoring device (SA 
Instruments). The tumor was placed into a slotted-tube 
resonator (inner diameter = 11 mm, depth = 9 mm) built 
in-house and the probe was centered in the magnet. Body 
temperature was regulated at 37 ± 1°C by blowing warm 
air into the magnet via a thermostatically controlled device 
(SA Instruments).
In vivo single voxel spectroscopy
Mice bearing subcutaneous 4175-Luc+ or MB-
MDA-231 tumors (~300 μL) underwent pre-treatment 
MRS scans in a 9.4 T horizontal bore magnet equipped 
with 40 G/cm gradients interfaced to an Agilent Direct-
Drive console (Agilent) operating vnmrj 2.3.C software. 
Multi-slice gradient and spin echo images were used for 
tumor localization. T
2
-weighted spin echo anatomical 
images were acquired using a spin echo multi-slice 
(SEMS) pulse sequence (TR = 1000 ms, TE = 10 ms, 
number of slices = 20, field of view = 20 × 20 mm2, slice 
thickness = 1 mm, NT = 1, matrix size = 256 × 128) 
and used for voxel selection. A single voxel 1H PRESS 
spectrum was acquired in a 3x3x3 mm3 voxel (TR = 3000 
ms, TE1 = 12.68 ms and TE2 = 10.01 ms, number 
of averages = 128, complex points = 4096, spectral 
width = 4000 Hz and acquisition time of 6 min 24 sec). 
Water suppression was achieved using the VAPOR 
sequence [46]. An unsuppressed water spectrum was 
acquired (8 averages) as a chemical shift and concentration 
reference. One week following initiation of treatment, 
1H MR spectra were acquired again. Spectra were 
processed using Mnova Lite 5.2.5 software (Mestrelab 
Research). Free induction decays were processed by 10 Hz 
apodization followed by Fourier transformation. Spectra 
were phased and chemical shift and baseline correction 
performed prior to fitting of the water (4.7 ppm), tCho (3.2 
ppm), PUFA (2.8 ppm), and lipid (1.3 ppm) resonances. 
The metabolite/water ratio was determined and the percent 
change was determined as [post-treatment ratio – pre-
treatment ratio] *100% / pre-treatment ratio.
Animal treatments 
Companion diagnostic study
In vivo MRS was used to establish baseline tCho 
levels in a cohort of 10 mice bearing 4175-Luc+ tumors. 
Mice were injected i.p. for 5 consecutive days with either 
100 μL saline or 2 mg/kg MN58b. A follow-up MR scan 
was acquired 1 week after treatment. After the final MRS, 
each animal was injected i.v. with a trace dose (20 nmol) 
of JAS239 in ethanol/saline. After 24 h, the mice were 
euthanized and each tumor was analyzed for NIRF as 
described above. 
Tumor growth inhibition
A cohort of 15 mice was inoculated with 4175-
Luc+ tumors.  Beginning 3 days post-inoculation, animals 
received a 100-μL i.p. injection of either control DMSO/
saline, 2 mg/kg MN58b  or 4 mg/kg JAS239 in DMSO/
saline daily for 5 days. Tumor volumes were assessed by 
caliper measurement.
Pharmacodynamic indicators of chokα inhibition
A cohort of 15 mice was inoculated with MDA-
MB-231 cells. When a volume of 300 μL was reached, 
tumors were scanned using MRS. Tumor volumes were 
measured using T
2
-weighted images. The animals were 
separated into treatment groups, and for 5 consecutive 
days each group was injected i.p. with 100 μL of DMSO/
saline vehicle (n = 5), 2 mg/kg MN58b (n = 4), or 4 mg/kg 
JAS239 (n = 3). Initial cohort sizes were 5 per condition, 
but some animals had to be removed from the study 
because the treatment was so effective that we were unable 
to place voxels within post-treatment tumors that were 
too small. Follow-up MRI/MRS scanning was performed 
on day 7 to assess tumor growth inhibition and changes 
in metabolite levels. After imaging, blood was collected 
into heparin-coated tubes by cardiac puncture. Resected 
tumors were embedded in Optimum Cryo-Temperature 
(Sakura Finetek), flash-frozen in liquid nitrogen, and 
stored at –80°C. Blood samples were submitted to the 
Ryan Veterinary Clinic Diagnostic labs for toxicology.
Histopathology
Hematoxylin and eosin staining and 
immunohistochemistry was performed as described 
previously [23]. Caspase-3 (R&D Systems AF835) and 
Ki67 (Abcam ab16667) antibody staining was performed 
on a Bond Max automated staining system (Leica 
Microsystems) using the Bond Intense R staining kit 
(Leica Microsystems DS9263). An Aperio Scan Scope 
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OS (Aperio Technology) was used to scan slides, and the 
Image Scope nuclear staining algorithm (version 9; Aperio 
Technology) was used to quantify Ki67 and caspase-3 
positive nuclei in representative regions of each slide.
Statistical analysis
Statistical analyses of treated versus control values 
were performed in Microsoft Excel 2010 (Version 
14.0.7128.5000 32-bit) using an unpaired Student’s 
t-test unless noted otherwise. A P-value of ≤ 0.05 was 
considered to be statistically significant. All error bars 
represent mean ± SEM. 
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